Mensch und Maschine Software, a small German software company, reported Q2 2024 sales of €75.1 million and net income of €7.34 million, up from €71.32 million and €6.58 million respectively last year. Basic earnings per share rose to €0.43 from €0.39 year-on-year for the quarter, while six-month figures showed sales at €175.97 million with net income at €17.95 million compared to last year's figures of 174.38 and 16.39 respectively . The company's debt-to-equity ratio has improved significantly over five years from 42% to 15%, reflecting strong financial health alongside its high-quality earnings and robust interest coverage (247x EBIT).

• Navigate through the intricacies of Mensch und Maschine Software with our comprehensive health report here.

• Review our historical performance report to gain insights into Mensch und Maschine Software's's past performance.

RH?N-KLINIKUM

Simply Wall St Value Rating: ★★★★★☆

Overview: RH?N-KLINIKUM Aktiengesellschaft, together with its subsidiaries, offers in-patient, semi-patient, and outpatient healthcare services in Germany and has a market cap of €783.18 million.

Operations: RH?N-KLINIKUM generates revenue primarily from its acute hospitals (€1.45 billion), with additional income from Medical Care Centres (€23.90 million) and Rehabilitation Hospitals (€34.70 million). The company's net profit margin stands at 4.5%.

RH?N-KLINIKUM's recent performance highlights its strong position in the healthcare sector. Earnings surged by 81.6% over the past year, outpacing the industry's 30.9%. The debt-to-equity ratio rose from 8.7% to 11.1% in five years, but it has more cash than total debt, ensuring financial stability. With a price-to-earnings ratio of 16.8x compared to the industry average of 22.6x, it trades at good value and reported Q2 revenue of €459 million and net income of €9 million for Q2-2024.

• Click to explore a detailed breakdown of our findings in RH?N-KLINIKUM's health report.

• Understand RH?N-KLINIKUM's track record by examining our Past report.

Summing It All Up

• Embark on your investment journey to our 51 German Undiscovered Gems With Strong Fundamentals selection here.

• Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.

• Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.

Looking For Alternative Opportunities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include XTRA:M12 XTRA:MUM and XTRA:RHK.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]